Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908313 | 0.83 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL8681344 | 0.83 | ALDH1A1 (0.38) | MEN1KMT2APKMALDH1A1GAA | |
| SCHEMBL16960532 | 0.82 | MAPK1 (0.43) | MAPK1HSD17B10ALDH1A1GAAPTGDR2 | |
| SCHEMBL29598848 | 0.81 | HSD17B10 (0.53) | HSD17B10MEN1KMT2APKMALDH1A1 | |
| SCHEMBL23362831 | 0.80 | ALDH1A1 (0.41) | HSD17B10MEN1KMT2APKMALDH1A1 | |
| SCHEMBL30296208 | 0.80 | ALDH1A1 (0.41) | HSD17B10MEN1KMT2APKMALDH1A1 | |
| SCHEMBL17551834 | 0.79 | MAPT (0.59) | MEN1KMT2APKMALDH1A1PTGDR2 | |
| SCHEMBL30152364 | 0.79 | PTGDR2 (0.59) | MAPK1HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL8712221 | 0.79 | PTGDR2 (0.59) | MAPK1HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL2116744 | 0.79 | SLC6A4 (0.36) | MEN1KMT2APKMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257189-A1 | MACROCYCLES FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-5843983-A | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | MAPK1 1433/4885HSD17B10 2025/4885PDE4A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.